Transient arterial phase respiratory motion-related artifact in MR imaging of the liver

an analysis of four different gadolinium-based contrast agents

Mansi R. Shah, Milana Flusberg, Viktoriya Paroder, Alla Rozenblit, Victoria Chernyak

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose The purpose was to compare hepatic arterial phase (HAP) respiratory motion artifact (RMA) between gadoxetate, gadobutrol, gadopentetate, and gadobenate. Materials/methods Two hundred cases of each gadolinium agent were included. RMA was assigned using 5-point Likert scale (1=no motion, 5=extreme motion) on precontrast and HAP. RMA increase (increase ≥1 on HAP from precontrast) was the outcome in logistic regression. Results Odds of RMA increase for gadoxetate were 5.5 (P<.001), 3.6 (P=.034), and 9.5 (P<.001) times higher than gadobutrol, gadopentetate, and gadobenate, respectively. Gadolinium volume and dose were not independent predictors of RMA increase. Conclusion Gadoxetate has increased odds of RMA compared with other gadolinium agents; tight contrast bolus is not a contributor.

Original languageEnglish (US)
Pages (from-to)23-27
Number of pages5
JournalClinical Imaging
Volume41
DOIs
StatePublished - Jan 1 2017

Fingerprint

Gadolinium
Artifacts
Contrast Media
Liver
Logistic Models

Keywords

  • Gadoxetate
  • Hepatic arterial phase
  • Respiratory motion artifact
  • Transient respiratory motion

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{4136c6a5db0b48aab37d0dc19e9334ec,
title = "Transient arterial phase respiratory motion-related artifact in MR imaging of the liver: an analysis of four different gadolinium-based contrast agents",
abstract = "Purpose The purpose was to compare hepatic arterial phase (HAP) respiratory motion artifact (RMA) between gadoxetate, gadobutrol, gadopentetate, and gadobenate. Materials/methods Two hundred cases of each gadolinium agent were included. RMA was assigned using 5-point Likert scale (1=no motion, 5=extreme motion) on precontrast and HAP. RMA increase (increase ≥1 on HAP from precontrast) was the outcome in logistic regression. Results Odds of RMA increase for gadoxetate were 5.5 (P<.001), 3.6 (P=.034), and 9.5 (P<.001) times higher than gadobutrol, gadopentetate, and gadobenate, respectively. Gadolinium volume and dose were not independent predictors of RMA increase. Conclusion Gadoxetate has increased odds of RMA compared with other gadolinium agents; tight contrast bolus is not a contributor.",
keywords = "Gadoxetate, Hepatic arterial phase, Respiratory motion artifact, Transient respiratory motion",
author = "Shah, {Mansi R.} and Milana Flusberg and Viktoriya Paroder and Alla Rozenblit and Victoria Chernyak",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.clinimag.2016.09.004",
language = "English (US)",
volume = "41",
pages = "23--27",
journal = "Clinical Imaging",
issn = "0899-7071",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Transient arterial phase respiratory motion-related artifact in MR imaging of the liver

T2 - an analysis of four different gadolinium-based contrast agents

AU - Shah, Mansi R.

AU - Flusberg, Milana

AU - Paroder, Viktoriya

AU - Rozenblit, Alla

AU - Chernyak, Victoria

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose The purpose was to compare hepatic arterial phase (HAP) respiratory motion artifact (RMA) between gadoxetate, gadobutrol, gadopentetate, and gadobenate. Materials/methods Two hundred cases of each gadolinium agent were included. RMA was assigned using 5-point Likert scale (1=no motion, 5=extreme motion) on precontrast and HAP. RMA increase (increase ≥1 on HAP from precontrast) was the outcome in logistic regression. Results Odds of RMA increase for gadoxetate were 5.5 (P<.001), 3.6 (P=.034), and 9.5 (P<.001) times higher than gadobutrol, gadopentetate, and gadobenate, respectively. Gadolinium volume and dose were not independent predictors of RMA increase. Conclusion Gadoxetate has increased odds of RMA compared with other gadolinium agents; tight contrast bolus is not a contributor.

AB - Purpose The purpose was to compare hepatic arterial phase (HAP) respiratory motion artifact (RMA) between gadoxetate, gadobutrol, gadopentetate, and gadobenate. Materials/methods Two hundred cases of each gadolinium agent were included. RMA was assigned using 5-point Likert scale (1=no motion, 5=extreme motion) on precontrast and HAP. RMA increase (increase ≥1 on HAP from precontrast) was the outcome in logistic regression. Results Odds of RMA increase for gadoxetate were 5.5 (P<.001), 3.6 (P=.034), and 9.5 (P<.001) times higher than gadobutrol, gadopentetate, and gadobenate, respectively. Gadolinium volume and dose were not independent predictors of RMA increase. Conclusion Gadoxetate has increased odds of RMA compared with other gadolinium agents; tight contrast bolus is not a contributor.

KW - Gadoxetate

KW - Hepatic arterial phase

KW - Respiratory motion artifact

KW - Transient respiratory motion

UR - http://www.scopus.com/inward/record.url?scp=84991503908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991503908&partnerID=8YFLogxK

U2 - 10.1016/j.clinimag.2016.09.004

DO - 10.1016/j.clinimag.2016.09.004

M3 - Article

VL - 41

SP - 23

EP - 27

JO - Clinical Imaging

JF - Clinical Imaging

SN - 0899-7071

ER -